[{"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-001", "question": "A 45-year-old man with a history of relapsing-remitting multiple sclerosis presents with acute onset of bilateral leg weakness and urinary retention. MRI shows a new T2-hyperintense lesion at T10 with gadolinium enhancement. Despite high-dose intravenous methylprednisolone, symptoms worsen over 48 hours. CSF analysis reveals elevated IgG index and oligoclonal bands. What is the most appropriate next step in management?", "options": ["Initiate plasma exchange", "Administer rituximab", "Start fingolimod", "Perform lumbar puncture for repeat CSF analysis", "Switch to natalizumab"], "answer": "A", "answer_index": 0, "explanation": "Plasma exchange is the most appropriate next step for severe acute demyelinating attacks unresponsive to corticosteroids in multiple sclerosis, as it rapidly removes circulating autoantibodies and inflammatory mediators. Rituximab and natalizumab are disease-modifying therapies not indicated for acute management, while fingolimod is contraindicated in active inflammation; repeat CSF analysis is unnecessary with established diagnosis.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: acute severe attack (bilateral leg weakness, urinary retention), new enhancing spinal cord lesion, failure to improve after high-dose IV steroids, and supportive CSF findings. The item asks for the next step in managing a steroid-refractory severe acute demyelinating event. Plasma exchange (PLEX) is the established rescue therapy in this scenario. The alternatives are correctly dismissed: rituximab and natalizumab are disease-modifying therapies for long-term control, not acute rescue; fingolimod is not an acute treatment and carries risks in active inflammation; repeat LP is not indicated as diagnosis is already confirmed. No logical contradictions exist, and the stem provides sufficient detail to uniquely support PLEX. Medical accuracy is sound, aligning with standard guidelines for managing steroid-unresponsive MS relapses. Minimal fix: None required; the item is already clear and accurate.\",\n  \"medical_accuracy_score\":  \"5\",\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: acute severe attack (bilateral leg weakness, urinary retention), new enhancing spinal cord lesion, failure to improve after high-dose IV steroids, and supportive CSF findings. The item asks for the next step in managing a steroid-refractory severe acute demyelinating event. Plasma exchange (PLEX) is the established rescue therapy in this scenario. The alternatives are correctly dismissed: rituximab and natalizumab are disease-modifying therapies for long-term control, not acute rescue; fingolimod is not an acute treatment and carries risks in active inflammation; repeat LP is not indicated as diagnosis is already confirmed. No logical contradictions exist, and the stem provides sufficient detail to uniquely support PLEX. Medical accuracy is sound, aligning with standard guidelines for managing steroid-unresponsive MS relapses. Minimal fix: None required; the item is already clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-002", "question": "A 62-year-old woman with incomplete tetraplegia from a C5 spinal cord injury undergoes inpatient rehabilitation. She develops orthostatic hypotension during tilt table training, with blood pressure dropping from 120/80 mmHg supine to 85/50 mmHg at 60 degrees. Heart rate increases minimally. Autonomic testing shows absent sympathetic skin response below the lesion. What is the most effective pharmacologic intervention to facilitate upright tolerance?", "options": ["Midodrine", "Fludrocortisone", "Propranolol", "Clonidine", "Ephedrine"], "answer": "A", "answer_index": 0, "explanation": "Midodrine, an alpha-1 agonist, is the most effective for neurogenic orthostatic hypotension in spinal cord injury by promoting vasoconstriction without significant supine hypertension risk. Fludrocortisone causes fluid retention but risks edema; propranolol and clonidine may worsen hypotension, while ephedrine is less selective and has more side effects.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: spinal cord injury with orthostatic hypotension, minimal heart rate increase, absent sympathetic skin response below lesion indicating autonomic dysfunction. Main logical issue: none; the vignette clearly points to neurogenic orthostatic hypotension requiring vasoconstriction. Main medical accuracy issue: none; midodrine is guideline-supported for this condition. Minimal fix: none needed; the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\":  \"5\",\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: spinal cord injury with orthostatic hypotension, minimal heart rate increase, absent sympathetic skin response below lesion indicating autonomic dysfunction. Main logical issue: none; the vignette clearly points to neurogenic orthostatic hypotension requiring vasoconstriction. Main medical accuracy issue: none; midodrine is guideline-supported for this condition. Minimal fix: none needed; the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-003", "question": "A 28-year-old woman presents with recurrent episodes of vertigo, tinnitus, and fluctuating hearing loss, now with superimposed gait instability. MRI reveals bilateral vestibular schwannomas and a spinal ependymoma. Genetic testing confirms NF2 mutation. She develops progressive bilateral facial weakness. What is the most appropriate targeted therapy to consider for tumor stabilization?", "options": ["Bevacizumab", "Everolimus", "Crizotinib", "Trametinib", "Sorafenib"], "answer": "A", "answer_index": 0, "explanation": "Bevacizumab, a VEGF inhibitor, is the most appropriate for NF2-associated schwannomas by reducing tumor vascularity and stabilizing growth, with evidence from clinical trials showing hearing preservation. Everolimus targets mTOR but lacks specificity for NF2; crizotinib, trametinib, and sorafenib are not indicated for this condition and target unrelated pathways.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Confirmed NF2 mutation with bilateral vestibular schwannomas and spinal ependymoma, progressive bilateral facial weakness, and question asks for targeted therapy for tumor stabilization. The item clearly identifies NF2-associated tumors, and bevacizumab is supported by evidence for NF2-related schwannomas, particularly for hearing preservation and tumor control. Alternatives are not standard for NF2: everolimus (mTOR inhibitor) has limited evidence, crizotinib (ALK/ROS1 inhibitor) for lung cancer, trametinib (MEK inhibitor) for melanoma/other cancers, sorafenib (multi-kinase inhibitor) for renal/hepatic cancers. No internal contradictions or missing critical details. Medical accuracy is sound. Minimal fix: None required; item is clear and accurate.\",\n  \"logical_false_reason\": \"T\",\n  \"logical_validity\": true,\n  \"medical_accuracy_score\": \n  \"5\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Confirmed NF2 mutation with bilateral vestibular schwannomas and spinal ependymoma, progressive bilateral facial weakness, and question asks for targeted therapy for tumor stabilization. The item clearly identifies NF2-associated tumors, and bevacizumab is supported by evidence for NF2-related schwannomas, particularly for hearing preservation and tumor control. Alternatives are not standard for NF2: everolimus (mTOR inhibitor) has limited evidence, crizotinib (ALK/ROS1 inhibitor) for lung cancer, trametinib (MEK inhibitor) for melanoma/other cancers, sorafenib (multi-kinase inhibitor) for renal/hepatic cancers. No internal contradictions or missing critical details. Medical accuracy is sound. Minimal fix: None required; item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-004", "question": "A 55-year-old man with diabetic amyotrophy presents for outpatient rehabilitation with severe proximal leg weakness and pain. Electromyography shows denervation in the L2-L4 myotomes. Despite optimized glycemic control, he has persistent muscle atrophy. What is the most evidence-based adjunctive therapy to enhance functional recovery beyond standard physical therapy?", "options": ["Intravenous immunoglobulin", "Pyridostigmine", "Gabapentin", "Corticosteroids", "Plasmapheresis"], "answer": "A", "answer_index": 0, "explanation": "Intravenous immunoglobulin has shown benefit in diabetic amyotrophy by modulating autoimmune-mediated nerve damage, leading to improved strength and pain control in refractory cases. Corticosteroids risk worsening diabetes; pyridostigmine is for myasthenia, gabapentin addresses pain but not weakness, and plasmapheresis lacks supporting evidence.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "judge_model": "deepseek-v3.2", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: diabetic amyotrophy (diabetic lumbosacral radiculoplexus neuropathy), severe proximal leg weakness and pain, denervation in L2-L4 myotomes, persistent atrophy despite glycemic control. The question asks for the most evidence-based adjunctive therapy to enhance functional recovery beyond standard physical therapy. The keyed answer (A, IVIG) is not the most evidence-based first-line adjunctive therapy; corticosteroids (D) are the most established immunomodulatory treatment for diabetic amyotrophy in refractory cases, supported by more robust evidence than IVIG. IVIG is sometimes used but is not the most evidence-based first choice. The item's logic incorrectly elevates IVIG over corticosteroids. Main logical issue: Miskeyed. Main medical accuracy issue: Overstates evidence for IVIG as the most evidence-based therapy; corticosteroids have stronger support. Minimal fix: Change key to D (Corticosteroids) and adjust rationale to reflect that corticosteroids are first-line immunomodulation, with IVIG as an alternative if contraindicated.\", \"logical_false_reason\": \"K\", \"logical_validity\": false, \"medical_accuracy_score\":  \"3\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict on keyed answer: Miskeyed. Key stem clues: diabetic amyotrophy (diabetic lumbosacral radiculoplexus neuropathy), severe proximal leg weakness and pain, denervation in L2-L4 myotomes, persistent atrophy despite glycemic control. The question asks for the most evidence-based adjunctive therapy to enhance functional recovery beyond standard physical therapy. The keyed answer (A, IVIG) is not the most evidence-based first-line adjunctive therapy; corticosteroids (D) are the most established immunomodulatory treatment for diabetic amyotrophy in refractory cases, supported by more robust evidence than IVIG. IVIG is sometimes used but is not the most evidence-based first choice. The item's logic incorrectly elevates IVIG over corticosteroids. Main logical issue: Miskeyed. Main medical accuracy issue: Overstates evidence for IVIG as the most evidence-based therapy; corticosteroids have stronger support. Minimal fix: Change key to D (Corticosteroids) and adjust rationale to reflect that corticosteroids are first-line immunomodulation, with IVIG as an alternative if contraindicated.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}]